

# congress mirror



MSA 2007



## Munich International Summer Academy of Practical Dermatology July 22–27, 2007

Welcome message by Thomas Ruzicka and Matthias Volkenandt

### Dear ladies and gentlemen, dear colleagues,

for more than five decades, the Department of Dermatology of the Ludwig-Maximilians University of Munich, one of the largest centers of clinical dermatology, has invited German-speaking dermatologists for an intensive one week practical update in dermatology ("Fortbildungswoche für praktische Dermatologie und Venerologie"). The number of participating dermatologists

has constantly risen from 200 in 1951 to more than 3,500 in 2006. For most German-speaking dermatologists, the "Munich Week" at the end of July every other year has developed into one of their most important biannual updates in practical dermatology.

We are now, for the first time, expanding this successful concept offering a one-week course to the

international English-speaking dermatological community to be held from July 22–27, 2007. This course will be held in cooperation with the International Society of Dermatology. Besides plenary lectures by renowned dermatologists covering important areas of clinical dermatology, major emphasis will be put on the acquisition of practical knowledge and skills. The rich cultural life

of Munich in summer time will provide a stimulating atmosphere for this meeting.


While the traditional German language program will continue to be offered in the last week of July every other year (2008/2010), we are planning to offer the English speaking courses every other year in between, starting July 2007.

We cordially invite you to join

this first Munich International Summer Academy of Practical Dermatology, which will be held in a central location of Munich during one of the loveliest seasons in our charming city.

Thomas  
Ruzicka

Matthias  
Volkenandt



Publication date:  
October 2005  
259 pages  
44 illustrations b/w with  
supplemental CD-ROM  
Price: € 56,-

ISBN 978-3-86542-001-X


Klaus Kayser · Janusz Szymas · Ronald S. Weinstein

### Telepathology and Telemedicine

#### Communication, Electronic Education and Publication in e-Health

This completely revised second edition of the first monograph on telemedicine and telepathology reflects the dramatic advances taking place in these rapidly evolving, telecommunications-enabled, medical fields. Telemedicine and telepathology have both matured as clinical tools and are being used in many countries. New types of health care organizations are emerging. For example, "virtual pathology institutions" are being established to allow international surgical pathology authorities to form ad hoc expert panels that review current problem cases over the Internet. New technologies include plans to completely digitalize histological slides and generate automated computerized diagnosis. They will influence the publication procedures for medical science and research, and enrich the educational experiences of students and medical practitioners. How does the world of medical informatics work? What are its roots? How rapidly will informatics-driven patient-centric healthcare develop and expand? How will it influence the patients' diagnosis, treatment and care? Which changes might be expected to become commonplace in medical practice? Will the developing countries and underdeveloped nations participate or be left behind?

This monograph discusses the theoretical basis, historical overview, and clinical applications of telemedicine and telepathology. Cost-benefit considerations for telehealth are included as well as a discussion of the socioeconomic impact of telecommunications on the health care industry. The influence and feedback of social behavior are described, as well as the interrelationships between medical requirements and technical innovations in the 21st century. This book is written by scholars who study the past in order to anticipate the future.



Publication date:  
2007  
206 pages, 62 figures  
incl. DVD-ROM  
with References ·  
Software-Demos · Links

Price: € 58,-

ISBN 978-3-86542-006-0

Klaus Kayser · Bela Molnar · Ronald S. Weinstein

### Virtual Microscopy

#### Fundamentals · Applications · Perspectives of Electronic Tissue-based Diagnosis

Virtual microscopy or the diagnostic work with a completely digitized glass slide opens a new world in tissue-based diagnosis. Based upon the experiences of telepathology application it has already reached a promising level of technology. Machines equipped with appropriate magazines can scan a glass slide in a few minutes. Corresponding high resolution monitors are commercially available. Software tools that are embedded or closely linked to hospital information systems work with open standards. They act as nodes in a network that meets the challenges of globalization in diagnostic pathology. Additional fields of diagnostic medicine such as live imaging techniques as well as therapeutic strategies can be implemented. The final system will probably act as integrated medical Grid trying to offer an efficient and high performance service for the patient.

What is the theoretical background of virtual microscopy and its proper application? What are the specific working conditions of tissue-based diagnosis in its conventional and its computerized manner? How rapidly will computerized diagnostic pathology develop and expand to patient-centric healthcare? How will multiple diagnoses contemporary stated in different institutions influence the patients' diagnosis, treatment and care? Which changes might be expected in become commonplace in medical practice? Will the developing countries and underdeveloped nations participate or be left behind? To which extend a computerized diagnosis system can replace human findings and statements?

This monograph discusses the theoretical basis, historical overview, and clinical applications of virtual microscopy and computerized diagnostic pathology. It describes the historic roots and basic laws of communication and diagnostics in health care. The hallmarks of development in light microscopy are included as well as analysis and quantification of histological images. Commercially available hard- and software systems are analyzed in respect to cost-benefit relation, performance and workflow embedding. Potential future development in terms of application, continuous education, research, and socioeconomic impact is included as well as a discussion of distributed information and knowledge concepts (Grid technology). Based upon its roots this book addresses to anticipate the future of tissue-based diagnosis.



VSV

interdisciplinary

medical publishing

Ifenpfad 2-4

12107 Berlin

Fax (030) 761 80 680

www.vsv-online.eu

Via telefax +49 30 76180-680 to VSV interdisciplinary medical publishing bookshop

Yes, I order a copy of  
Klaus Kayser · Janusz Szymas · Ronald S. Weinstein  
Telepathology and Telemedicine  
ISBN 978-3-86542-001-X; Price: € 56,-

Yes, I order a copy of  
Klaus Kayser · Bela Molnar · Ronald S. Weinstein  
Virtual Microscopy  
ISBN 978-3-86542-006-0; Price: € 58,-

Name \_\_\_\_\_

Company/Institute/Practice \_\_\_\_\_

Address \_\_\_\_\_

Signature \_\_\_\_\_

Registration and Information/Anmeldung und Information: [www.munich-academy-dermatology.de](http://www.munich-academy-dermatology.de)

**Sunday, July 22, 2007**

18:00 – 20:00

**Opening Reception and Registration**

Foyer of the Auditorium Maximum (AudiMax)  
Technical University of Munich  
Arcisstr. 21  
80333 Munich  
(near subway "Theresienstrasse")

**Monday, July 23, 2007**

9:00

**Registration**

9:30

**Opening speech Introduction – Dermatology in Munich**

**Munich and its surroundings**  
Thomas Ruzicka, Munich

**Inflammatory Skin Diseases**

Chair: Thomas Ruzicka, Munich / Sakari Reitamo, Helsinki

10:00

**Psoriasis vulgaris: Clinical manifestations and therapeutic options**

James Krueger, New York

- Clinical features of psoriasis
- Histological features of psoriasis
- An explanation of the immunological circuits expressed in this disease and causing the clinical pathology
- Treatment with targeted therapeutics



Two new immune concepts that relate to psoriasis will be explained: TIP-DCs a new group of inflammatory dendritic cells that

are the most common leukocyte in psoriasis lesions and functions of a new type of T-lymphocyte called the Th17 T-cell.

10:30

**Cutaneous lupus erythematosus: Clinical spectrum and therapeutic options**

Annegret Kuhn, Heidelberg/Düsseldorf

- Classification of Cutaneous Lupus Erythematosus (CLE)
- Clinical manifestations of CLE
- New aspects of topical and systemic treatment of CLE



Cutaneous lupus erythematosus (CLE) is a heterogeneous autoimmune disorder with a wide range of skin manifestations and a

variable evolution. In the past years, the classification of CLE has been subject of intensive research and now includes acute CLE (ACLE), subacute CLE (SCLE), chronic CLE (CCLE), and intermittent CLE (ICLE). Recent advances in biotechnology resulted in the development of several novel systemic agents for the treatment of autoimmune diseases; however, further progress and controlled clinical trials are necessary for the approval of new therapeutic strategies in CLE.

10:50 Break

Chair: Peter Fritsch, Innsbruck / Jörg Prinz, Munich

11:30

**Topical immunomodulators**

Sakari Reitamo, Helsinki



Topical immunomodulators, now more commonly termed topical calcineurin inhibitors (TCIs) represent a major advance in the

therapy of atopic dermatitis. This lesson will look at a variety of studies that have been conducted between TCIs and active comparators. Furthermore the use of TCIs in children and their long-term safety will be reviewed.

12:00

**Atopic eczema – Treatment 2007**

Thomas Ruzicka, Munich

12:20

**Behcet's disease**

Meltem Önder, Ankara

- Diagnose cutaneous manifestations of Behcet's Disease
- Understand the pathogenesis of Behcet's Disease
- Select the optimal management strategy and discuss the therapeutic modalities for Behcet's Disease



Behcet's Disease is characterized by recurrent orogenital ulcerations and skin eruptions, ocular, articular, gastrointestinal, neuro-

logical, and vascular involvements. It occurs endemically in the Mediterranean countries, The Middle East and Far East. The highest prevalence is reported in Turkey with familial occurrences. It may be seen in Europe as well. Most patients in Germany are of Turkish origin. The etiopathogenesis of Behcet's Disease is very complicated. Genetic, environmental, bacterial, viral and immunologic factors have been proposed. This session will cover the clinical, laboratory findings and pathogenesis. In addition the current treatment modalities will be discussed.

12:40 Bavarian Lunch

13:45

**Symposium Psoriasis: New Avenues to Therapy**

(sponsored by Wyeth)

Chair: Thomas Ruzicka, Munich  
Introduction: Psoriasis vulgaris and Munich

- New insights into pathomechanisms of inflammatory skin diseases and novel therapeutic approaches  
James Krueger, New York
- Practical management of Psoriasis vulgaris in current dermatological practice  
Jörg Prinz, Munich

15:00 Bus transfer to the hospital

15:30 – 17:00

**Practical courses**

- Phototherapy
- Surgery
- Mycology

**Workshops****The Challenge of Scleroderma – New Insights and Treatment Options**

(sponsored by Actelion)

Chair: Annegret Kuhn, Heidelberg/Düsseldorf; Mary Gantcheva, Sofia

- Pathophysiology and clinical manifestations of scleroderma  
M. Sticherling, Erlangen
- Treatment of scleroderma and complications  
U. Müller-Ladner, Gießen/Bad Nauheim
- Role of ERA in skin manifestations of scleroderma  
Annegret Kuhn, Heidelberg/Düsseldorf

- Mechanism of Endothelin Receptor Antagonists (ERA)
- Indications for ERA
- Clinical trials of ERA in patients with systemic scleroderma



Endothelin-1 is found in increased levels in the serum of patients with systemic scleroderma (SSc), suggesting that it plays a role

in the pathogenesis this autoimmune disease. Endothelin receptor antagonists (ERA) are effective in the treatment of pulmonary hypertension in the setting of SSc. More recently, treatment with ERA has been shown to decrease the development of new digital ulcers and to improve hand function in patients with SSc.

**Immunosuppressive Therapy in Dermatological Diseases**

(sponsored by Novartis)

- Psoriasis vulgaris  
Thomas Ruzicka, Munich
- Bullous diseases  
Gerald Messer, Munich

**Meet the Expert Session****Dermatologic Diseases in Organ Transplant Patients**

Alexandra Geusau, Wien

- Historical overview and current status of transplant medicine in Europe and the United States
- Epidemiology and pattern of skin diseases in organ transplant recipients
- Infectious skin diseases, clinical, diagnostic and therapeutic aspects
- Skin cancers including non melanoma skin cancers; epidemiology and pathogenic factors
- Cutaneous adverse effects of immunosuppressants
- Guidelines for the management of skin diseases in this patients group
- interactive teaching with case reports



The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with

many adverse cutaneous effects. The two-hour workshop gives an overview and basic knowledge surrounding the care of solid organ transplant recipients with dermatologic diseases, including their optimal diagnostic and therapeutic approach.

**Tuesday, July 24, 2007**

9:00

**Clinical Case Presentations****Oncology**

Chair: Ketty Peris, Rome / Birger Konz, Munich

9:30

**Treatment of non melanoma skin cancer**

Sergio Chimenti, Rom

10:00

**Treatment of malignant melanoma**

Jürgen Becker, Würzburg



The objective of the lesson will be to outline the current understanding of melanomagenesis which explain the clinical appearance of cutaneous melanoma and

allow rational therapeutic approaches to treat metastatic disease.

10:30

**Kaposi's sarcoma**

Robert Schwartz, New Jersey



The goals of this lecture are to update colleagues on Kaposi's sarcoma, to be able to recognize unusual clinical variants and to be aware of the potential of sirolimus in preventing it.

10:50 Break / Industrial exhibition

Chair: Jasna Lipozencic, Zagreb / Andreas Wollenberg, Munich

11:30

**Treatment of cutaneous lymphoma**

Sergej Goerd, Mannheim

12:00

**Cutaneous side effects of novel anticarcinogenic drugs**

Bernhard Homey, Düsseldorf

12:20

**Cryotherapy in dermatology**

Christos Zouboulis, Dessau

- Understand the physical properties of the application of cold temperatures on tissues and their proper use
- Present the therapeutic indications of cryosurgery in dermatology
- Communicate new developments in the field



Cryotherapy is one of the most widely used and established therapeutic methods in dermatology. This lecture will

present the basic elements of applying cold temperatures as a therapeutic regimen and performing successful cryosurgery in skin diseases. In addition, it should help to increase the knowledge for obtaining optimal results and to avoid pitfalls. Good outcomes in cryosurgery are possible through continuous education and controlled training.

12:40 Bavarian Lunch / Industrial exhibition

13:30-14:45

**Symposium****Photodynamic Therapy for non Melanoma Skin Cancer and Beyond**

(sponsored by Galderma)

Chair: Rolf-Markus Szeimies, Regensburg

- What's new in non-melanoma skin cancer (NMSC) treatment guidelines?  
Rolf-Markus Szeimies, Regensburg
- Can photodynamic therapy prevent non melanoma skin cancer? Lessons from studies in organ transplant patients  
Ann-Marie Wennberg, Göteborg
- Achieving best practice in topical photodynamic therapy – management of pain  
Hans-Christian Wulf, Kopenhagen

15:00 – 18:00

**Common Session of the Israeli-German Dermatological Group (IGDG) and the Munich International Summer Academy of Practical Dermatology**

Chair: Eva-Bettina Bröcker, Würzburg; Arie Ingber, Jerusalem

15:15

**What's new in leishmaniasis?**

Esther von Stebut, Mainz

- Brief introduction cutaneous Leishmaniasis – epidemiology, disease, clinical presentation
- Immunology of cutaneous Leishmaniasis
- Therapeutic options
- Future therapeutic options



15:35

**What's new in drug-induced pemphigus?**

Sarah Brenner, Tel-Aviv

15:55

**What's new in vasculitis?**

Peter Fritsch, Innsbruck

16:15 Break / Industrial exhibition

Chair: Sima Halevy, Beer-Sheva / Percy Lehmann, Wuppertal

16:45

**What's new in histopathology of genetic skin diseases?**

Rueven Bergman, Haifa

17:05

**What's new concerning dendritic cells?**

Eckhart Kämpgen, Erlangen

17:25

**What's new in body dysmorphic disorder?**

Edith Orion, Rechevot

17:45

**Closing Remarks**

Eva-Bettina Bröcker, Würzburg

15:00 Bus transfer to the hospital

15:30 – 18:00  
Practical courses

- **Trichology**  
N.N.
- **Basic Dermoscopy and Pitfalls**  
Wilhelm Stolz, Munich /  
Andreas Blum, Konstanz
- Physics and features of  
Dermoscopy
- Algorithmus of Dermoscopy
- Vessels in Dermoscopy
- Benign or malignant melanocytic  
tumor?
- Guidelines of the International  
Dermoscopy Society (IDS)
- Quiz in Dermoscopy



In this lecture on dermoscopy relevant questions about physics and features of visible structures will be presented, also helpful algorithms and features of vessels. Hints to differentiate benign from malignant skin tumors will be given and also the present guidelines of the International Dermoscopy Society (IDS). Finally dermoscopic cases allow you to test your skills in dermoscopy.

- **Sonography**  
N.N.

Workshops

**Aesthetic Dermatology:  
Improved Cosmetic Results  
by Modular Concepts**  
(sponsored by Merz)

- Improving cosmetic results  
around the mouth area  
Luitgard Wiest, Munich
- What can be achieved by fillers  
Johannes Reinmüller, Wiesbaden
- What can be achieved by  
Botulinum-Toxin  
Thomas Pröbstle, Heidelberg

**Current Topics in Biologics  
in Dermatology**

Chair: Rana Anadolu-Brasie,  
Ankara / Mehmet Ali Güre,  
Ankara / Meltem Önder, Ankara

- Introduction to biologics  
Rana Anadolu-Brasie, Ankara
- Biologics in Psoriasis  
Nilgün Atakan, Ankara
- Biologics – Spanish experience  
Montserrat Peres Lopez, Barcelona
- Biologics – Turkish experience  
Rana Anadolu-Brasie, Ankara /  
Nihal Kundakci, Ankara
- Biologics – Off label use  
Pelin Mutsak, Ankara

Meet the Expert Session

**Acne and Rosacea**  
Christos Zouboulis, Dessau /  
Lutz Kowalick, Plauen

- Epidemiology
- Pathogenesis
- Clinical stages
- Differential Diagnosis
- Topical treatment
- Systemical treatment
- Surgery
- Stage dependent therapy



Rosacea is a chronic inflammatory skin disease with high impact on patient's social relationships and life quality. Only

some clues are known about its pathogenesis. Symptoms of nearly all patients are manageable using stage dependent therapies like topical and/or systemical drugs and/or surgery incl. Laser treatments.

Wednesday, July 25, 2007

9:00  
**Clinical Case Presentations  
Unusual skin tumors  
of the head**  
Matilda Bylaite, Vilnius

**Infectiology**  
Chair: Hans Christian Korting,  
Munich / N.N.

9:30  
**Infectious and non infectious  
diseases of the genital area**  
Ulrich Hengge, Düsseldorf

10:00  
**Fungal diseases and  
antifungal therapy**  
Martin Schaller, Tübingen

- Diagnosis and treatment -  
options and failures
- Emerging pathogens in dermatologic mycology
- Established and novel therapeutic approaches



Cutaneous fungal infection especially dermatophytosis are extremely common. The lesson should inform about novel developments in diagnosis and treatment of these fungal diseases.

ments in diagnosis and treatment of these fungal diseases.

10:30  
**Cutaneous leishmaniasis and  
other tropical diseases:  
Recognition and treatment**  
Claes Enk, Jerusalem



Immigration of foreign workers and refugees, tourism to tropical countries, and soldiers returning from international conflicts, force

today's dermatologists to deal with exotic skin disorders that are usually not part of the curriculum taught in Western dermatology resident programs. The problems inherent in recognizing common skin disorders in colored skin will be discussed, and cutaneous leishmaniasis and onchocerciasis will be presented as examples of tropical skin diseases encountered in dermatology practice.

10:50 Break / Industrial exhibition

**Skin-Aging and Anti-Aging**

Chair: Preya Kullavanijaya, Thailand /  
Claudia Borelli, Munich

11:30  
**Skin aging: From molecular  
pathology to novel therapies**  
Jean Krutmann, Düsseldorf

12:00  
**Cosmeceuticals:  
Hype or Hope?**  
Martina Kerscher, Hamburg

12:20  
**Botulinum and  
chemical peels**  
Luitgard Wiest, Munich

12:40 **Bavarian Lunch /  
Industrial exhibition**

**Symposium**

13:45  
**Investigating a New Way of  
Using Tacrolimus Ointment  
in Adults and Children:  
Study Results**  
(sponsored by Astellas)

Chair: Thomas Ruzicka, Munich

Andreas Wollenberg, Munich /  
Sakari Reitamo, Helsinki



Proactive therapy is a new treatment regimen with predefined low dose topical application of anti-inflammatory substances to

problem zones previously affected by atopic dermatitis lesions. The CONTROL study provides high level evidence of the good clinical efficacy and safety, improved quality of life and favourable low drug use of a proactive low-dose, twice weekly tacrolimus ointment regimen.

15:00 **Departure of busses for boat  
tour on the lake of Starnberg**

Thursday, July 26, 2007

9:30  
**Clinical Case Presentations**

**Photodermatology**  
Chair: Percy Lehmann, Wuppertal /  
N.N.

9:30  
**Sun beds: Risks and benefits**  
Herbert Hönigsmann, Wien

9:55  
**Workup of the  
photosensitive patient**  
Percy Lehmann, Wuppertal



Diagnosis of photodermatoses is based on the patient's history, morphology of the lesions, histopathology and the results of photo

testing. However, generally accepted guidelines for photo testing are lacking. Laboratory data may help to exclude differential diagnoses, for example, porphyries; however, in most cases of photodermatoses they are of no help. Since skin lesions often subside rapidly after sun exposure, it is desirable to induce the dermatosis in a given test area with appropriate test protocols. This is most important in case a patient presents with a vague medical history of sun sensitivity without pertinent skin lesions. Progress has been made to induce in loco a variety of photodermatoses or photo-aggravated dermatoses, for example, polymorphous light eruption (PLE), hydroa vacciniforme, chronic actinic dermatitis (CAD) (including persistent light eruption), solar urticaria (SU) and lupus erythematosus (LE).

10:20  
**Novel developments  
in phototherapy**  
Lajos Kemény, Szeged

- Mechanism of action of phototherapy – optics of the skin
- New light sources for phototherapy
- New indications for phototherapy
- Practical suggestions.



In this lecture the most recent innovations in dermatological phototherapy are discussed with practical suggestions for clinicians.

In the first part of the lecture a brief overview will be provided about the mechanism of action of UV phototherapy and about the optics of the skin. In the second part, new innovative technologies (excimer laser, excimer lamp, targeted phototherapy using fiberoptic technology) will be described. In the third part of the lecture new indications for phototherapy will be discussed with practical suggestions.

10:40  
**UV-radiation in Bavaria:  
Short facts on impact and  
prevention campaigns**  
Alexander Steinmann, Munich

10:50 Break / Industrial exhibition

Skin and ...

Chair: NN / Jörg Prinz, Munich

11:30  
**Skin and ... joints**  
NN

12:00  
**Skin and ... hair**  
Hans Wolff, Munich

12:20  
**Skin and ... gastrointestinal  
diseases**  
Roland Kruse, Düsseldorf

- Tumors
- Inflammatory bowel diseases
- Vascular disorders



The lecture provides an overview on the frequent skin signs which can be caused by an underlying gastrointestinal disease.

12:40 **Bavarian Lunch /  
Industrial exhibition**

13:45  
**Symposium  
Acne – State of the Art**  
(sponsored by Hermal)

**What is new in  
pathophysiology?**  
Jana Hercogova, Prag

**Isotretinoin – what we  
learned in 30 years**  
Thomas Ruzicka, Munich

15:00 **Bus transfer to the hospital**

15:30  
**Practical courses  
Photodynamic Therapy  
(sponsored by Galderma)**  
Rolf-Markus Szeimies, Regensburg, /  
Carola Berking, Munich

- Theoretical background of the mechanism and effects of topical PDT on skin
- Practical training of PDT
- Practical tips for the management of side effects of PDT
- Discussion of new indications



**Aesthetic Dermatology  
(sponsored by Lumenis)**  
Claudia Borelli, Munich /  
Tatjana Pavicic, Munich

**Cellulite – New treatment  
modalities**  
Tatjana Pavicic, Munich

- Aetiopathogenetic factors and pathogenesis
- Management options
- Practical treatment by a radiofrequency-light-based technology



Cellulite or so called orange peel skin affects 80-90% of all females. In the first theoretical part different hypotheses about the origin of cellulite are explained. In the second practical part we demonstrate a radiofrequency-light-based technology for the treatment of cellulite.

M. Straßburg · I.-V.Wagner · W. Schneider

## DS OML

### Decision Support for the Interpretation of Oral Mucosa Lesions

Version 2.0

This interactive CD-ROM provides you with an ideal decision-making tool for the diagnosis, differential diagnosis and therapy of diseases of the oral mucosa. The content is primarily designed for the needs in general practice, but beyond that DS OML is also suitable for application in study and teachings as well as for the integration in clinical treatment.

**Comfortable**

- Improvement of clinical management,
- Import of clinical images from your intraoral camera into DS OML via the Twain interface
- Online-Support: [www.ds-oml.de](http://www.ds-oml.de)

Via telefax +49 30 76180-680 to  
VSV interdisciplinary medical publishing  
bookshop

Yes, I order a copy of Straßburg et al.;  
DS OML 2.0  
ISBN 978-3-87652-919-6; € 198,-

---

Name

---

Company/Institute/Practice

---

Address

---

Signature

### Therapy of skin-aging with ablative and non-ablative laser systems – new treatment options

Claudia Borelli, Munich

- Ablative laser systems: CO<sub>2</sub> laser, Erbium:YAG-laser, CO<sub>2</sub>/Erbium:YAG-combination-laser (Derma K-laser)
- Non-ablative laser systems: Skin rejuvenation with the pulsed dye laser (N lite V-laser)



Prolonged exposure to UV-radiation induces a variety of visible skin changes such as lentiginosae or seniles, actinic keratoses,

and pronounced wrinkles. Laser skin resurfacing is a popular procedure to improve these physical signs of the photoaged face. Ablative laser therapy (CO<sub>2</sub>/Erbium:YAG laser therapy) is considered an effective method for skin rejuvenation. Skin resurfacing is defined as an ablation of the upper tissue layers of the face. Possible side effects are hyperpigmentation, hypopigmentation and even scars. The so called "down"-time after the skin resurfacing procedure is regarded as major drawback of this method. The Erbium:YAG laser and CO<sub>2</sub> laser both have distinct advantages and disadvantages following their originalities. In the lecture the differences between the two systems are discussed. Patients photographs before and after treatment are demonstrated.

### Skin rejuvenation

Tatjana Pavicic, Munich

- Pathogenetic factors and histopathological changes in aged skin
  - Overview of methods for treating wrinkles and skin laxity
  - Aluma – Theory of clinical mechanism and FACES-Technology
  - Practical treatment with Aluma
- Different methods like face lift, dermabrasion, ablative and non-ablative lasers, light sources and radiofrequency are used for treating wrinkles and skin laxity. In this lesson we demonstrate the non-invasive treatment uses a breakthrough technology termed FACES (functional aspiration controlled electrothermal stimulation) to safely and painlessly heat the dermis and stimulate collagen regeneration.

### Therapy of acne and rosacea with light and lasers

Claudia Borelli, Munich

- Visible light: Blue light, Red light, LED's, Photodynamic therapy (PDT)
- Lasers: Pulsed dye laser (Nlite V-laser), others

In this lecture we will present an overview of on the treatment of acne with visible light (blue light, red light, and also LED's including the results of our own studies (especially blue light). We will also discuss different laser systems for the treatment of acne and the current literature and the results of an own study using pulsed dye laser (N lite V laser). Correspondingly rosacea treatments with light and lasers will be reviewed.

### Laser therapy of aesthetic vascular indications

Peter Kaudewitz, Munich



Lasers have gained an important status as both office and hospital based treatment modality. Meanwhile the vast number of available techniques and devices makes laser application a seemingly complicated affair. This workshop will provide an opportunity to see products of leading laser manufacturers at work during live demonstrations in a clinical setting. All major fields of laser application such as

- Vascular lesions,
- Epilation,
- Skin rejuvenation
- Pigmentary lesions and tattoos will be covered. See the patient being treated, ask the expert and the patient and get detailed information on laser equipment.

### In-Vivo-Confocal-Lasermicroscopy

(sponsored by Mavig)

Susanne Astner, Berlin

- Morphology normal skin
- Morphology of benign inflammatory skin disorders
- Morphology of malignant proliferative skin disorders and pigmented lesions
- Hands on practical session



This course will serve as an introduction into reflectance confocal laser microscopy using the System VivaScope 1500. The atten-

dant will learn how to use the technology, obtain and interpret RCM images in healthy and diseased skin. After a short introduction, emphasis will be made on the practical aspect of confocal microscopy, and the active participation of the participants is encouraged.

### Workshops

#### New Therapy Concepts in Rosacea

(sponsored by Medigene)

Chair: Thomas Ruzicka, Munich

#### Rosacea – Clinical presentations and therapeutic challenge

Percy Lehmann, Wuppertal

#### New concepts in rosacea therapy

Hans Christian Korting, Munich

#### Phytotherapy and Inflammatory Skin Diseases

(sponsored by Karrer)  
Matthias Augustin, Freiburg / Jan Simon, Leipzig

#### Expression Lines and Facial Muscles. The Positive Influence of Botulinum Toxin A

(Sponsored by Ipsen Pharma)  
Luitgard Wiest, Munich

#### Meet the Expert Session

#### Contact dermatitis: Where are the pitfalls

Derte Bruynzeel, Amsterdam

### Friday, July 27, 2007

Chair: Matthias Volkenandt, Munich

9:00

#### Special Lecture: Inherited Skin Diseases – New benefits for patients

John McGrath, London



This presentation will focus on the translational benefits of research on patients with inherited skin diseases, providing examples of how finding the molecular basis of a particular disorder can lead to more accurate diagnoses, better genetic counselling and the development of new treatment strategies.

This presentation will explore how discovering the genetic basis of inherited skin diseases can lead to new clinical benefits for affected patients and their families. The talk will outline some key recent discoveries (particularly in understanding the genetics of the skin barrier), as well as the development of a range of options for prenatal diagnosis of severe, life-threatening genodermatoses, and the introduction of clinical trials to assess gene, protein and cell therapies for the inherited blistering skin diseases such as epidermolysis bullosa.

#### Sexually Transmitted Diseases

Chair: Michael Meurer, Dresden / Rudolf Rupec, Munich

9:30

#### Sexually transmitted diseases – Update 2007

Helmut Schöfer, Frankfurt

9:50

#### Unusual manifestations of syphilis and problems of diagnostic tests

Michael Meurer, Dresden



10:10

#### Cutaneous manifestations of HIV

N.N.

10:30 Break / Industrial exhibition

#### What's new in ...

Chair: Gerd Plewig, Munich / Johannes Ring, Munich

11:00

#### What's new in ... Dermato-Allergology

Johannes Ring, Munich

11:30

#### What's new in ... Dermatotomy and lasers

Keyvan Nouri, Miami

12:00

#### What's new in ... Aesthetic dermatology

Eva Kokoschka, Wien

- New theories
- New possibilities
- Skin < 50 – a new self confident part of our life way



12:30

#### What's new in ... Pediatric dermatology

Rudolf Happle, Marburg

- New aspects and recent advances in pediatric dermatology are reviewed. Ten different subjects will be presented.



Recent advances in molecular analysis have elucidated the cause monogenic hereditary disorders such as focal dermal

hypoplasia, the etiology of polygenic disorders such as atopic dermatitis, and the cause of some monogenic but non-hereditary traits such as the group of epidermal nevi. - Sebaceous nevi should no longer be removed as a „prophylactic measure“ to avoid skin cancer. - An update on views how to treat congenital melanocytic nevi of various sizes will likewise be presented. - In some children with vitiligo, topical treatment with calcineurin inhibitors has been shown to be effective.

13:00 Farewell and Lunch

ANZEIGE

## Sildenafil wirkt bei PAH pulmonal und intrapulmonal spezifisch

Die pulmonal-arterielle Hypertonie (PAH) ist eine tückische Erkrankung mit sehr schlechter Prognose. In den letzten Jahren haben Fortschritte im Verständnis der PAH-Pathogenese zu neuen Therapieansätzen geführt. Hierzu gehört auch die Hemmung der Phosphodiesterase (PDE)-5 mit oralem Sildenafil.

Bei der PAH findet eine schleichende Verengung und Verdickung der Lungengefäße (Remodeling) statt, die einen Druckanstieg im kleinen Kreislauf verursacht. Der rechte Ventrikel muss gegen den steigenden Lungengefäßdruck anpumpen, kann dies jedoch immer schlechter erfüllen. Hierdurch kann eine Mangelperfusion der Lungenstrombahn entstehen. Der hohe Druck bedingt auch, dass das Blut in nicht belüftete Areale der Lunge gelangt. Hier kann es sich nicht mit Sauerstoff aufsättigen, so dass der Sauerstoffgehalt im großen Kreislauf abnimmt. Normalerweise wird die Lunge nur in Bereichen mit belüfteten Alveolen gut perfundiert, da die Dehnung der Alveolen durch die eingeatmete Luft

zur lokalen Freisetzung von NO mit anschließender Gefäßdilatation führt.

#### Pulmonal und intrapulmonal spezifisch

Genau hier greift der PDE-5-Hemmer Sildenafil (Revatio®) an. Die basale PDE-5-Aktivität ist in der Lunge am höchsten, so dass Sildenafil pulmonal und auch intrapulmonal spezifisch wirksam ist. Es verbessert als erstes oral verabreichtes Medikament bevorzugt die Durchblutung in gut belüfteten Lungenarealen. Bisher war dies nur durch die Inhalation gefäßerweiternder Substanzen möglich, jedoch ist das hierfür in der Regel eingesetzte inhalative Prostanoid Iloprost nur relativ kurz wirksam. Bei Sildenafil dagegen

setzt der Effekt langsamer ein, hält allerdings deutlich länger an.

#### Lungendruck sinkt, Gehstrecke nimmt zu

Sildenafil senkt den intrapulmonal-arteriellen Druck und Widerstand, ohne dabei den systemischen Gefäßwiderstand zu beeinflussen, erklärte Prof. A. Ghofrani, Gießen, auf dem Weltkardiologenkongress in Barcelona. In der Zulassungsstudie SUPER (Sildenafil Use in Pulmonary Arterial Hypertension) mit 278 Patienten verbesserte der PDE-5-Hemmer in Dosierungen von 3 x täglich 20, 40 oder 80 mg signifikant die körperliche Belastbarkeit im Vergleich zu Placebo. So verlängerte sich die Sechs-Minuten-Gehstrecke unter

der 20-mg-Dosierung in zwölf Wochen um 45 m. Höhere Dosen wirkten nicht wesentlich besser. 39 % der mit Sildenafil behandelten Patienten verbesserten sich um mindestens eine NYHA-Klasse.

#### Hinweis auf bessere Prognose

In der Verlängerung der SUPER-Studie, in der 259 Patienten 3 x täglich 80 mg Sildenafil einnahmen, konnte die verbesserte Belastbarkeit über zwölf Monate aufrecht erhalten werden. Nach einem Jahr waren noch 95 % der Patienten am Leben. Sildenafil ist zur Behandlung der PAH der Funktionsklasse III in der Dosierung von 3 x täglich 20 mg zugelassen. In dieser Dosis liegt Sildenafil am unteren Ende des Preisspektrums anderer, ebenfalls für diese Indikation zugelassener Medikamente. Die Leitlinien der „European Society of Cardiology“ (ESC) stufen Sildenafil mit einem Klasse-IA-Label als „First-line“-Medikament ein.

### Imprint

VSV Interdisciplinary Medical Publishing  
Ifenpfad 2-4  
12107 Berlin  
Tel. 030/761 80-601  
Fax. 030/761 80-680  
info@vsv-online.eu  
www.vsv-online.eu

Publisher: Dr. Andreas B. F. Müller

EIC: Matthias Franzke

Advertisement, Off-prints: Manuela Schulze  
schulze@vsv-online.eu

Layout: VSV-Team, Berlin

Industry reports are based upon the information from the producers.

The congress mirror is printed on environment-friendly paper.

Jurisdiction and place of fulfillment: Berlin  
© Copyright 2007, Veterinärspiegel Verlag GmbH

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Veterinärspiegel Verlag. Violations are liable for prosecution under the German Copyright Law.

The use of general descriptive names, registered trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.